MX356562B - Metodo para producir un producto medicinal que comprende una proteina biologicamente activa y el producto resultante. - Google Patents

Metodo para producir un producto medicinal que comprende una proteina biologicamente activa y el producto resultante.

Info

Publication number
MX356562B
MX356562B MX2015000434A MX2015000434A MX356562B MX 356562 B MX356562 B MX 356562B MX 2015000434 A MX2015000434 A MX 2015000434A MX 2015000434 A MX2015000434 A MX 2015000434A MX 356562 B MX356562 B MX 356562B
Authority
MX
Mexico
Prior art keywords
biologically active
active protein
product
frozen
solvent
Prior art date
Application number
MX2015000434A
Other languages
English (en)
Other versions
MX2015000434A (es
Inventor
Kevin O'connell
Sandhya Buchanan
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2015000434A publication Critical patent/MX2015000434A/es
Publication of MX356562B publication Critical patent/MX356562B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para producir un producto medicinal que comprende una proteína biológicamente activa que comprende los pasos de proporcionar una composición acuosa que comprende un solvente, la proteína biológicamente activa y entre 20 % en peso y 60 % en peso de un azúcar no polimérico, congelar la composición, formando así al menos un cuerpo congelado que comprende el solvente en forma congelada, poner el cuerpo congelado en un aparato de secado mientras se transporta por medio de un soporte, el soporte comprende uno o más elementos de restricción que definen uno o más límites del soporte, en donde a lo sumo el 30 % de la superficie del cuerpo es contigua con el uno o más elementos de restricción, reducir la presión en el aparato de secado por debajo de la presión atmosférica, y proporcionar calor al cuerpo para sublimar el solvente congelado del cuerpo y obtener un cuerpo seco; la invención también pertenece a un producto que se puede obtener por medio de este método.
MX2015000434A 2012-07-10 2013-07-09 Metodo para producir un producto medicinal que comprende una proteina biologicamente activa y el producto resultante. MX356562B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261669797P 2012-07-10 2012-07-10
PCT/EP2013/064422 WO2014009328A1 (en) 2012-07-10 2013-07-09 A method to produce a medicinal product comprising a biologically active protein and the resulting product

Publications (2)

Publication Number Publication Date
MX2015000434A MX2015000434A (es) 2015-03-12
MX356562B true MX356562B (es) 2018-06-04

Family

ID=48747587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000434A MX356562B (es) 2012-07-10 2013-07-09 Metodo para producir un producto medicinal que comprende una proteina biologicamente activa y el producto resultante.

Country Status (12)

Country Link
US (4) US20140017318A1 (es)
EP (1) EP2872179B1 (es)
JP (1) JP6397405B2 (es)
CN (1) CN104428004B (es)
AU (1) AU2013289307B2 (es)
BR (1) BR112015000404B1 (es)
CA (1) CA2878353C (es)
ES (1) ES2620084T3 (es)
MX (1) MX356562B (es)
RU (1) RU2663581C2 (es)
WO (1) WO2014009328A1 (es)
ZA (1) ZA201409367B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
CA2927431C (en) 2013-10-16 2023-10-03 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
FR3024780B1 (fr) * 2014-08-07 2018-11-30 Bertin Pharma Reactif pret a l'emploi
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
MX2022007167A (es) * 2019-12-16 2022-10-03 Univ Northwestern Reactivos liofilizados.
CN114159555A (zh) * 2021-12-08 2022-03-11 江西赛基生物技术有限公司 抗原蛋白冻干小球及其制备方法
CN117159480B (zh) * 2023-11-01 2024-03-01 江西赛基生物技术有限公司 一种重组人IFN-γ蛋白冻干小球及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
JPS589688A (ja) * 1981-07-06 1983-01-20 Toyobo Co Ltd 安定な酵素組成物
US5443959A (en) * 1992-09-09 1995-08-22 Tokuyama Corporation Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US5565318A (en) 1994-09-02 1996-10-15 Pharmacia Biotech, Inc. Room temperature stable reagent semi-spheres
PT2275119E (pt) * 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
JP2001168002A (ja) * 1999-12-06 2001-06-22 Mitsubishi Electric Corp 半導体装置およびその製造に用いるフォトマスクならびにその重ね合わせ精度向上方法
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US7923029B2 (en) * 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7129778B2 (en) * 2003-07-23 2006-10-31 Northrop Grumman Corporation Digital cross cancellation system
GB2404880B (en) * 2003-07-25 2005-10-12 Ultrasound Brewery Ultrasonic solution separator
CA2552328A1 (en) * 2004-01-15 2005-08-04 Intervet International B.V. Non-animal origin stabilizers and processes for producing the same
RU2283603C1 (ru) * 2005-02-21 2006-09-20 Калининградский государственный технический университет Способ сублимационной сушки пищевых продуктов
US20070259348A1 (en) * 2005-05-03 2007-11-08 Handylab, Inc. Lyophilized pellets
US20070025934A1 (en) * 2005-07-29 2007-02-01 L'oreal Nail varnish containing a polyoxyalkylene-chain polymer
EP2004144A1 (en) * 2005-12-02 2008-12-24 Stichting Katholieke Universiteit Method for obtaining hollow particles
KR101501780B1 (ko) * 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
EP2117514B1 (en) * 2007-03-05 2011-06-15 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
WO2008143782A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
TWI436789B (zh) 2008-01-21 2014-05-11 Intervet Int Bv 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包
ES2615390T3 (es) * 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
RU2371916C1 (ru) * 2008-06-04 2009-11-10 Государственное научное учреждение ордена "Знак Почета" Научно-исследовательский институт сельского хозяйства Крайнего Севера Сибирского отделения Российской академии сельскохозяйственных наук (ГНУ НИИСХ КС СО Россельхозакадемии) Способ консервирования пантов северных оленей с использованием инфракрасного излучения
CN101983457B (zh) * 2008-06-19 2014-02-05 夏普株式会社 无线装置
US20110113643A1 (en) * 2008-07-10 2011-05-19 Ulvac, Inc. Freeze-drying apparatus
TWI468157B (zh) * 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
TWI471127B (zh) * 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
TR201906255T4 (tr) * 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.

Also Published As

Publication number Publication date
JP2015522055A (ja) 2015-08-03
RU2015104159A (ru) 2016-08-27
CA2878353C (en) 2021-04-20
US20140017318A1 (en) 2014-01-16
BR112015000404A2 (pt) 2017-06-27
AU2013289307A1 (en) 2015-01-22
US20150140102A1 (en) 2015-05-21
JP6397405B2 (ja) 2018-09-26
US20180369146A1 (en) 2018-12-27
RU2663581C2 (ru) 2018-08-07
ZA201409367B (en) 2015-11-25
EP2872179B1 (en) 2017-01-11
WO2014009328A1 (en) 2014-01-16
US20200390712A1 (en) 2020-12-17
CN104428004A (zh) 2015-03-18
ES2620084T3 (es) 2017-06-27
MX2015000434A (es) 2015-03-12
CN104428004B (zh) 2021-03-12
AU2013289307B2 (en) 2017-12-14
EP2872179A1 (en) 2015-05-20
BR112015000404B1 (pt) 2022-08-09
CA2878353A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
MX356562B (es) Metodo para producir un producto medicinal que comprende una proteina biologicamente activa y el producto resultante.
PL3283470T3 (pl) Sposoby wytwarzania kwasu 2,5-furanodikarboksylowego i jego pochodnych
WO2015044782A3 (en) Intranasal dhe for the treatment of headache
WO2015192834A3 (de) Verfahren zur herstellung eines zur verdampfung vorgesehenen verbrauchsstoffs
MX2018001006A (es) Composicion farmaceutica que comprende un vector adenoviral.
MX2016000314A (es) Tratamiento de suspension liquida de gluten para reducir o remover aflatoxina.
ZA201708390B (en) Processes for preparing 2,5-furandicarboxylic acid and esters thereof
WO2013144106A9 (de) Pulvermetallurgische herstellung eines thermoelektrischen bauelements
WO2014131422A3 (en) Fermented rapeseed feed ingredient
ZA201803510B (en) Process for the production of 2,5-furandicarboxylic acid (fdca)
WO2014184654A3 (en) Coffee product
NZ704092A (en) Ph adjusted pulse protein product
SG10201810447YA (en) Process for preparing esters of lactic acid, and 2-hydroxy-3-butenoic acid or alfa-hydroxy methionine analogues from sugars
PH12017500672A1 (en) Spray nozzle apparatus for spray-drying applications
EP3357478A4 (en) ROLLED FORMING METHOD FOR THE PRODUCTION OF A FREEZER-DRIED AUXILIARY SUBSTANCE AND PRODUCT FROM THEREOF
MX2018003707A (es) Producto de superficie solida y su proceso de fabricacion.
MX2019010228A (es) Composición para liberación controlada de sustancias fisiológicamente activas y proceso para su preparación.
WO2016161990A3 (zh) 用于治疗心血管疾病的固体制剂
PH12014502546A1 (en) Insecticidal water-in-oil (w/o) formulation
IL262602B (en) Amide derivatives of polycaphoiquinic acids, a process for their preparation and their uses
MX2022013576A (es) Composicion para la liberacion controlada de sustancias fisiologicamente activas y proceso para su preparacion.
CL2012000804A1 (es) Complejo que incluye grano entero y un hidrocoloide; proceso de fabricacion para elaborar el complejo que comprende mezclar el garno entero y el hidrocolide y someter a tratamiento termico humedo para formar el complejo; producto alimenticio que comprende el complejo; metodo para incrementar la saciedad que comprende el consumo de 7,5 gramos del complejo; uso del complejo porque sirve para incrementar la saciedad.
CZ307451B6 (cs) Způsob přípravy chmelového materiálu se zvýšeným obsahem 8-prenylnaringeninu a chmelový materiál
TH154870A (th) วิธีการผลิตผลิตภัณฑ์ทางการแพทย์ที่ประกอบรวมด้วยโปรตีนออกฤทธิ์ทางชีวภาพและผลิตภัณฑ์ที่ได้รับมา
GB201615661D0 (en) Cryo-cooler generator improvements in and relating to heat engines their delivery and drive systems, their integration into the plant for the production of

Legal Events

Date Code Title Description
FG Grant or registration